HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
Identifieur interne : 000546 ( Main/Exploration ); précédent : 000545; suivant : 000547HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
Auteurs : Anthony Kong [Royaume-Uni] ; Véronique Calleja [Royaume-Uni] ; Pierre Leboucher [France] ; Adrian Harris [Royaume-Uni] ; Peter J. Parker [Royaume-Uni] ; Banafshé Larijani [Royaume-Uni]Source :
- PLoS ONE [ 1932-6203 ] ; 2008.
Abstract
The response rate to EGFR tyrosine kinase inhibitors (TKIs) may be poor and unpredictable in cancer patients with EGFR expression itself being an inadequate response indicator. There is limited understanding of the mechanisms underlying this resistance. Furthermore, although TKIs suppress the growth of HER2-overexpressing breast tumor cells, they do not fully inhibit HER2 oncogenic function at physiological doses.
Here we have provided a molecular mechanism of how HER2 oncogenic function escapes TKIs' inhibition via alternative HER receptor activation as a result of autocrine ligand release. Using both Förster Resonance Energy Transfer (FRET) which monitors
These results demonstrate the role of drug-induced autocrine events leading to the activation of alternative HER receptors in maintaining HER2 phosphorylation and in mediating resistance to EGFR tyrosine kinase inhibitors (TKIs) in breast cancer cells, and hence specify treatment opportunities to overcome resistance in patients.
Url:
DOI: 10.1371/journal.pone.0002881
PubMed: 18682844
PubMed Central: 2483931
Affiliations:
- France, Royaume-Uni
- Angleterre, Grand Londres, Oxfordshire, Île-de-France
- Londres, Oxford, Paris
- Université d'Oxford
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000227
- to stream Pmc, to step Curation: 000227
- to stream Pmc, to step Checkpoint: 000170
- to stream Ncbi, to step Merge: 000085
- to stream Ncbi, to step Curation: 000085
- to stream Ncbi, to step Checkpoint: 000085
- to stream Main, to step Merge: 000546
- to stream Main, to step Curation: 000546
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells</title>
<author><name sortKey="Kong, Anthony" sort="Kong, Anthony" uniqKey="Kong A" first="Anthony" last="Kong">Anthony Kong</name>
<affiliation wicri:level="3"><nlm:aff id="aff1"><addr-line>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="aff2"><addr-line>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Calleja, Veronique" sort="Calleja, Veronique" uniqKey="Calleja V" first="Véronique" last="Calleja">Véronique Calleja</name>
<affiliation wicri:level="3"><nlm:aff id="aff1"><addr-line>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leboucher, Pierre" sort="Leboucher, Pierre" uniqKey="Leboucher P" first="Pierre" last="Leboucher">Pierre Leboucher</name>
<affiliation wicri:level="3"><nlm:aff id="aff4"><addr-line>Laboratoire de Physiologie de la Perception et de l'Action, College de France, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Physiologie de la Perception et de l'Action, College de France, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harris, Adrian" sort="Harris, Adrian" uniqKey="Harris A" first="Adrian" last="Harris">Adrian Harris</name>
<affiliation wicri:level="4"><nlm:aff id="aff3"><addr-line>Weatherall Institute of Molecular Medicine (IMM), Cancer Research UK, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Weatherall Institute of Molecular Medicine (IMM), Cancer Research UK, University of Oxford, John Radcliffe Hospital, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Parker, Peter J" sort="Parker, Peter J" uniqKey="Parker P" first="Peter J." last="Parker">Peter J. Parker</name>
<affiliation wicri:level="3"><nlm:aff id="aff2"><addr-line>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="aff5"><addr-line>Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larijani, Banafshe" sort="Larijani, Banafshe" uniqKey="Larijani B" first="Banafshé" last="Larijani">Banafshé Larijani</name>
<affiliation wicri:level="3"><nlm:aff id="aff1"><addr-line>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">18682844</idno>
<idno type="pmc">2483931</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483931</idno>
<idno type="RBID">PMC:2483931</idno>
<idno type="doi">10.1371/journal.pone.0002881</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000227</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000227</idno>
<idno type="wicri:Area/Pmc/Curation">000227</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000227</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000170</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000170</idno>
<idno type="wicri:Area/Ncbi/Merge">000085</idno>
<idno type="wicri:Area/Ncbi/Curation">000085</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000085</idno>
<idno type="wicri:Area/Main/Merge">000546</idno>
<idno type="wicri:Area/Main/Curation">000546</idno>
<idno type="wicri:Area/Main/Exploration">000546</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells</title>
<author><name sortKey="Kong, Anthony" sort="Kong, Anthony" uniqKey="Kong A" first="Anthony" last="Kong">Anthony Kong</name>
<affiliation wicri:level="3"><nlm:aff id="aff1"><addr-line>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="aff2"><addr-line>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Calleja, Veronique" sort="Calleja, Veronique" uniqKey="Calleja V" first="Véronique" last="Calleja">Véronique Calleja</name>
<affiliation wicri:level="3"><nlm:aff id="aff1"><addr-line>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leboucher, Pierre" sort="Leboucher, Pierre" uniqKey="Leboucher P" first="Pierre" last="Leboucher">Pierre Leboucher</name>
<affiliation wicri:level="3"><nlm:aff id="aff4"><addr-line>Laboratoire de Physiologie de la Perception et de l'Action, College de France, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Physiologie de la Perception et de l'Action, College de France, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harris, Adrian" sort="Harris, Adrian" uniqKey="Harris A" first="Adrian" last="Harris">Adrian Harris</name>
<affiliation wicri:level="4"><nlm:aff id="aff3"><addr-line>Weatherall Institute of Molecular Medicine (IMM), Cancer Research UK, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Weatherall Institute of Molecular Medicine (IMM), Cancer Research UK, University of Oxford, John Radcliffe Hospital, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Parker, Peter J" sort="Parker, Peter J" uniqKey="Parker P" first="Peter J." last="Parker">Peter J. Parker</name>
<affiliation wicri:level="3"><nlm:aff id="aff2"><addr-line>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Protein Phosphorylation Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="aff5"><addr-line>Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larijani, Banafshe" sort="Larijani, Banafshe" uniqKey="Larijani B" first="Banafshé" last="Larijani">Banafshé Larijani</name>
<affiliation wicri:level="3"><nlm:aff id="aff1"><addr-line>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London, United Kingdom</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cell Biophysics Laboratory, Lincoln's Inn Fields laboratories, London Research Institute, Cancer Research UK, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PLoS ONE</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Background</title>
<p>The response rate to EGFR tyrosine kinase inhibitors (TKIs) may be poor and unpredictable in cancer patients with EGFR expression itself being an inadequate response indicator. There is limited understanding of the mechanisms underlying this resistance. Furthermore, although TKIs suppress the growth of HER2-overexpressing breast tumor cells, they do not fully inhibit HER2 oncogenic function at physiological doses.</p>
</sec>
<sec><title>Methodology and Principal Findings</title>
<p>Here we have provided a molecular mechanism of how HER2 oncogenic function escapes TKIs' inhibition via alternative HER receptor activation as a result of autocrine ligand release. Using both Förster Resonance Energy Transfer (FRET) which monitors <italic>in situ</italic>
HER receptor phosphorylation as well as classical biochemical analysis, we have shown that the specific tyrosine kinase inhibitors (TKIs) of EGFR, AG1478 and Iressa (Gefitinib) decreased EGFR and HER3 phosphorylation through the inhibition of EGFR/HER3 dimerization. Consequent to this, we demonstrate that cleavage of HER4 and dimerization of HER4/HER2 occur together with reactivation of HER3 via HER2/HER3, leading to persistent HER2 phosphorylation in the now resistant, surviving cells. These drug treatment–induced processes were found to be mediated by the release of ligands including heregulin and betacellulin that activate HER3 and HER4 via HER2. Whereas an anti-betacellulin antibody in combination with Iressa increased the anti-proliferative effect in resistant cells, ligands such as heregulin and betacellulin rendered sensitive SKBR3 cells resistant to Iressa.</p>
</sec>
<sec><title>Conclusions and Significance</title>
<p>These results demonstrate the role of drug-induced autocrine events leading to the activation of alternative HER receptors in maintaining HER2 phosphorylation and in mediating resistance to EGFR tyrosine kinase inhibitors (TKIs) in breast cancer cells, and hence specify treatment opportunities to overcome resistance in patients.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Oxfordshire</li>
<li>Île-de-France</li>
</region>
<settlement><li>Londres</li>
<li>Oxford</li>
<li>Paris</li>
</settlement>
<orgName><li>Université d'Oxford</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Kong, Anthony" sort="Kong, Anthony" uniqKey="Kong A" first="Anthony" last="Kong">Anthony Kong</name>
</region>
<name sortKey="Calleja, Veronique" sort="Calleja, Veronique" uniqKey="Calleja V" first="Véronique" last="Calleja">Véronique Calleja</name>
<name sortKey="Harris, Adrian" sort="Harris, Adrian" uniqKey="Harris A" first="Adrian" last="Harris">Adrian Harris</name>
<name sortKey="Kong, Anthony" sort="Kong, Anthony" uniqKey="Kong A" first="Anthony" last="Kong">Anthony Kong</name>
<name sortKey="Larijani, Banafshe" sort="Larijani, Banafshe" uniqKey="Larijani B" first="Banafshé" last="Larijani">Banafshé Larijani</name>
<name sortKey="Parker, Peter J" sort="Parker, Peter J" uniqKey="Parker P" first="Peter J." last="Parker">Peter J. Parker</name>
<name sortKey="Parker, Peter J" sort="Parker, Peter J" uniqKey="Parker P" first="Peter J." last="Parker">Peter J. Parker</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Leboucher, Pierre" sort="Leboucher, Pierre" uniqKey="Leboucher P" first="Pierre" last="Leboucher">Pierre Leboucher</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000546 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000546 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Psychologie |area= TherFamFrancoV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:2483931 |texte= HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18682844" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a TherFamFrancoV1
This area was generated with Dilib version V0.6.29. |